Immunotherapy and gastroenteropancreatic neuroendocrine tumor

Timothy Allen*, Nepton Sheikh K, Shoja ER and Naveed Basha C

Global Allied Pharmaceuticals, Center for Excellence in Research and Development, 160 Vista Oak Dr. Longwood, FL 32779, USA

Abstract

Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) originates from the hormone producing cells of the gut along with rectum and pancreas. GEP-NET represents 75% of all neuroendocrine tumors (NETs). The incidence is 2.5 to 6.2 cases per 100,000 population and 5-year mean survival rate of 66% in the United States. No significant risk factors have been identified. But 25% of GEP-NETs have been associated with hereditary conditions like Multiple Endocrine Neoplasia type 1 (MEN-1), type-2 (MEN-2), Von Hippel Lindau disease (VHL gene), tuberous sclerosis complex (TSC) and neurofibromatosis type-1 (NF-1). Alterations and loss of various chromosomes result in the progression of GEP-NETs. Researchers are still challenged in exploring innate and adaptive immune systems. Immunotherapy has shown a promising development in the past few years. One optimistic treatment modality is immunotherapy, with much progress seen in the last decade. We review all the different classes of drugs, FDA approved or still under clinical trials directed at the therapy of the GEP-NET.

Abbreviations: US: United States; FDA: US Food and Drug Administration; GEP-NET: Gastroenteropancreatic Neuroendocrine Tumor; NET: neuroendocrine tumors; MEN-1: Multiple Endocrine Neoplasia type 1; MEN-2: Multiple Endocrine Neoplasia type 2; VHL: Von Hippel Lindau disease; TSC: Tuberous Sclerosis Complex; NF: Neurofibromatosis type-1; TF: Tissue Factor; CEA: carcinoembryonic receptor; NK: natural killer; ADC: antibody-drug conjugate; Vc: Volume of distribution; TF: Tissue Factor; CEA: carcinoembryonic antigen; RTK: receptor tyrosine kinase; ATP: Adenosine triphosphate; DNA: Deoxyribonucleic acid; STAT: signal transducer and activator of transcription; KIT: mast/stem cell growth factor; FLT-3: FMS-like tyrosine kinase 3; TIE-2: TEK tyrosine kinase; TRKB: tropomysin-related kinase B; AXL: Tyrosine-protein kinase receptor; UOF: MAPK or MEK: mitogen-activated protein kinase; CDC: cyclin-dependent kinase; TEC: Tec protein tyrosine kinase; PI3K: phosphatidylinositol-3,4,5-trisphosphate; BCR: B-cell antigen receptor; ATR: ataxia telangiectasia and rad3-related; Chk1: checkpoint kinase 1; CSF1R: colony-stimulating factor-1 receptor; wt: wild-type; EMT: epithelial-mesenchymal transition; TYRO3: TYRO3 protein kinase; MER: Proto-oncogene tyrosine-protein kinase of MERTK gene; DCS: Dendritic cells; IFN: interferon; ROS1: C-ros oncogene 1 gene; Immunoglobulin; APCs: antigen presenting cells; CTLs: cytotoxic T-lymphocytes; DCs: Dendritic cells; IFN: interferon; ROS1: C-ros oncogene 1 Ig: Immunoglobulin; APCs: antigen presenting cells; CTLs: cytotoxic T-lymphocytes; DCs: Dendritic cells; IFN: interferon; ROS1: C-ros oncogene 1 Ig: Immunoglobulin; APCs: antigen presenting cells; CTLs: cytotoxic T-lymphocytes; DCs: Dendritic cells; IFN: interferon; ROS1: C-ros oncogene 1

*Correspondence to: Timothy Allen, Global Allied Pharmaceuticals, Center for Excellence in Research and Development, 160 Vista Oak Dr. Longwood, FL 32779, USA, E-mail: timallenmed69@gmail.com

Key words: gastroenteropancreatic neuroendocrine tumor (gpe-net, neuroendocrine tumors (nets)), multiple endocrine neoplasia type 1 (men-1), type-2 (men-2), von hippel lindau disease (vhl gene), tuberous sclerosis complex (tsc) and neurofibromatosis type-1 (nf-1), fda: us food and drug administration

Received: January 02, 2019; Accepted: January 14, 2019; Published: January 16, 2019
Introduction

Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) originates from the hormone producing cells of the gut along with rectum and pancreas. In 2004, approximately 5.25 new cases per 100,000 population were diagnosed for GEP-NET as compared to earlier 3 cases per 100,000 population [1]. GEP-NET represents 75% of all neuroendocrine tumors (NETs) [2]. According to the Surveillance, Epidemiology and End Results (SEER) Program database, the incidence is 2.5 to 6.2 cases per 100,000 population and 5-year mean survival rate of 60% in the United States [3]. There is an increase of about 400% in the incidence since the past 3 decades [4,5]. It includes different types of histopathological and genetic characteristics. The male-to-female ratio is 5.35:4.76 with the predominance of male over female and higher incidence observed between the age of 40 to 50 years [1].

GEP-NETs develop in hormone producing cells in the gut and pancreatic areas. They are classified on the basis of embryonic site of origin and the hormones secreted by them, in the course. The classifications of GEP-NETs are as follows:

1. **Functional Carcinoid**: Aberrant/excessive secretion of serotonin
2. **Insulinoma**: Aberrant/excessive secretion of insulin, pro-insulin and C-peptide
3. **Gastrinoma**: Aberrant/excessive secretion of gastrin
4. **Glucagonoma**: Aberrant/excessive secretion of glucagon
5. **Somatostatinoma**: Aberrant/excessive secretion of somatostatin
6. **Vasoactive Intestinal Peptidoma**: Aberrant/excessive secretion of vasoactive intestinal peptide (VIP)

Etiology/Predisposing factors

For a large proportion of GEP-NETs, no significant risk factor have been evident [7]. Some conditions like ulcerative colitis, pre-existing diabetes mellitus and hypergastrinemia have been linked to this cancer [7-10]. However, the clear origin is still not known. Various risk factors associated with GEP-NET, include hereditary conditions like Multiple Endocrine Neoplasia type 1 (MEN-1), type-2 (MEN-2), Von Hippel Lindau disease (VHL gene), tuberous sclerosis complex (TSC) and neurofibromatosis type-1 (NF-1) [11-16]. Approximately, 25% of GEP-NETs have been associated with these risk factors. In such patients, NETs develop 15 years earlier than the stipulated age of the development of sporadic tumors [13,17]. In about 25%-75% of the patients with MEN-1, pancreatic NETs are proposed to develop [13].

In patients with Von-Hippel-Lindau disease, NETs are of benign origin [15,18]. NET is rarely found (1%) in patients with NF-1 and TSC and hence, does not form the part of the major clinical feature. However, if present, it is observed in approximately 30% of the cases of somatostatinomas in patients with NF-1 [16].

Pathophysiology and molecular basis [19]

GEP-NETs are the tumors of embryonic origin. The mutations and loss of heterozygosity (LOH) of several genes at different chromosomal locations forms the molecular basis of GEP-NETS.

**Chromosome 11q**: Unlike foregut NETs, the NET of midgut region does not exhibit MEN1 gene mutations. However, as per some studies, the NET of ileal and duodenal region does show the loss of 11q chromosome in 22% of cases. This region encodes for succinate dehydrogenase (SDHD), a tumor suppressor gene. These tumors also represent the loss of heterozygosity at the location of the SDHD gene present on the 11q23 chromosome [20]. Based on various studies, the NET of midgut origin also shows the loss of chromosomes at 9p location by 21%, 18p by 38% and 18q by 33% [21,22]. The chromosomal gain at 17q and 19p site is reported in 57% of cases. Loss of heterozygosity is seen in 88% cases at chromosome 18 [23]. All these reports indicate that NET tumors follow alterations at various chromosomes and modification of different molecular pathways.

**Chromosome 3p**: Chromosome 3p, which is deleted in 30% of pancreatic NETs is associated with a number of genes which includes VHL, retinoic acid receptor-β (RAR-β), MLH1 and RASSF1A. All of them belong to the class of tumor suppressor genes. RAR-β is associated with the process of apoptosis and development of embryo. In a study conducted by Chan et al., it was found to be hypermethylated by 25% in gastric NETs and none in the pancreatic NETs [24]. In another study conducted by House et al., it was observed to be hypermethylated by 25% in pancreatic NETs [25]. A study conducted by House et al., for hMLH1 hypermethylation, which is a repairing gene for mismatching of DNA, hypermethylation was found in 23% of pancreatic NETs [26]. RASSF1A is known to interact with Ras oncogene. It is present at 3p21.3 chromosomal loci. It is inactivated due to epigenetic hypermethylation caused by a promoter [27]. It also inhibits the concentration of cyclin D1, resulting in cell cycle arrest [28]. Hyper-methylation of RASSF1A was observed in 32% of NETs and 83% in pancreatic NETs [29, 30].

**Chromosome 11q13**: In the vicinity of MEN1 gene, there exists Phospholipase C β3 (PLCβ3) on chromosome 11q13. It regulates the signal transduction via receptors. It also helps the programmed cell death protein 4 (PDCD4) genes to be expressed, which is a tumor suppressor gene. In a study conducted by Stalberg et al., in 82 cases of NETs, 18% exhibited loss of expression [31].

**Cell Cycle Regulators**: Alterations in the cell cycle pathway are manifested in almost all the cancer [32]. Cyclin- dependent kinases-2,4 and 6 (cdk2, cdk4/6) control the transition of cell cycle from one phase to another. Cyclin D1 leads to the phosphorylation and inactivation of retinoblastoma tumor suppressor gene (Rb) and acts as an essential cofactor for cdk4/6. The inactivated Rb releases and advances E2F, a transcription factor, through restriction point. E2F regulates the metabolism of DNA along with cyclin E and A. Cyclin E phosphorylates the Rb completely by forming cyclinE-cdk2 complex.

The Cip/Kip family acts as an inhibitor of cdk2. It includes: p21CIP1, p27KIP1 and p57KIP2 [33]. INK4 proteins inhibit cdk4 and cdk6. INK4 proteins i.e. INK4a, INK4b, INK4c and INK4d, involve Rb and p53 tumor suppressor pathways and hence, restricts the tumor development. p16INK4A and p14ARF are encoded by INK4a [34]. p16INK4A acts as a sequestering agent and forms a cdk4-cdk6 complex. This complex leads to the release of p27KIP1, which acts as cyclinE/cdk2 inhibitor.

p53 stabilization and consequent cell cycle arrest are carried out by p14ARF. It inhibits MDM2, a negative regulator of p53. Another, cdk4/6 inhibitor, p18INK4C is encoded by INK4c gene [35].

Homoygous deletions or hyper-methylation of p16INK4A/p14ARF genes located at 9p21 chromosomal location have been associated with up to 92% of NETs in some studies. In a study conducted by Chan et al., hyper-methylation of p16INK4A and p14ARF was exhibited in 31% and
44% GI NETs, while only 9% of hyper-methylation was identified in pancreatic NETs [24].

p18INKn/p27KIP1 are also proposed to be involved in NET pathogenesis. In pancreatic NETs, the p18 location on 1p32 chromosome is deleted, while p27 and p21 locus are not. According to a study conducted by Kawahara et al, the locus p21, present on chromosome 6p12 was over expressed in 66% cases of GI NETs of malignant origin.

In a study, GI NETs of malignant and benign nature elucidated cyclin D1 oncogene (CCND1) over expression in 100% and 94% cases, respectively [36]. CCND1 is located on 11q13 site of chromosome [37]. According to a study, 65% of pancreatic NETs were proposed to over express cyclin D1 [38].

**Immunotherapy**

Figure 1 represents various molecular pathways based immunotherapy (Figure 1).

![Image of molecular pathways](image)

**Kinase inhibitors**

**FDA-Approved Kinase Inhibitors:** Sunitinib is the only FDA approved immunotherapeutic for the treatment of pancreatic NETs.

**Sunitinib:** The orally bioavailable indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity [39]. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Pms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.

**Indication and use:** Sunitinib is a kinase inhibitor indicated for the treatment of pNET in patients with unresectable locally advanced or metastatic disease.

**Pharmacokinetics:** $T_{\text{max}}$: 6 to 12 hours, $t^{1/2}$: 40-60 hours. AUC and $C_{\text{max}}$ increases as the dose increases in the range of 25-100mg.
Warnings: Severe hepatotoxicity and deaths have been reported, hazards to pregnant women and fetus, prolonged QT interval, cardiac toxicity, hypertension, thyroid dysfunction, adrenal hemorrhage. It is advised that people undergoing surgery should stop taking sunitinib.

Adverse events: Various adverse reactions that are associated with sunitinib are weakness, fever, stomatitis, edema, rashes, discoloration of skin, cough, bleeding, pain in back, taste alteration, constipation, change in colour of hairs and texture of skin.

Non-FDA approved Kinase Inhibitors

Some of the kinase inhibitors that are under clinical trials in phase I-III are as mentioned in the Table 1.

mTOR inhibitors

FDA-Approved mTOR Inhibitors

Everolimus: A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties [56]. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production.

Indications & use: Everolimus is a mTOR inhibitor that is indicated for adults with PNET that are unselectable, locally advanced or metastatic.

PD/PK: \( T_{1/2} \): 1-2 hours, Elimination \( t^{1/2} \): 30 hours. With the increase in the dose within the range of 5 mg to 70mg, \( C_{\text{max}} \) increases.

Warnings: Non-infectious pneumonitis, oral ulcers, renal failure, impaired wound healing, alterations in laboratory tests, vaccinations, embryo-fetal toxicity.

Adverse Events: The adverse reactions include reduced appetite, rashes, diarrhea, stomatitis, headache, and nausea, pain in abdomen, edema, cough, skin rashes and infection.

Non-FDA approved mTOR inhibitors: The below mentioned mTOR inhibitors are under clinical trials in Phase-II [57]:

Table 1. Non-FDA approved kinase inhibitors [40-55]

<table>
<thead>
<tr>
<th>Kinase Inhibitors</th>
<th>Clinical trial identifier number</th>
<th>Phase</th>
<th>Study design</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abrozantinib</td>
<td>NCT01466036</td>
<td>Phase-II</td>
<td>Safety/ Efficacy Study, Open Label</td>
<td>MET, VEGFR</td>
</tr>
<tr>
<td>Azopanib</td>
<td>NCT01841736; NCT01465659</td>
<td>Phase-II/Phase-I</td>
<td>Efficacy Study, Double Blind; Safety/ Efficacy Study, Open Label</td>
<td>VEGFR, PDGFR</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>NCT00131911; NCT00942682</td>
<td>Phase-II/Phase-I</td>
<td>Efficacy Study, Open Label; Safety Study, Open Label</td>
<td>TK Inhibitors</td>
</tr>
<tr>
<td>Trebananib</td>
<td>NCT01548482</td>
<td>Phase-I</td>
<td>Safety Study, Open Label</td>
<td>TK Inhibitors</td>
</tr>
<tr>
<td>Motesanib</td>
<td>NCT00427349</td>
<td>Phase-II</td>
<td>Treatment, Open Label</td>
<td>TK Inhibitors</td>
</tr>
<tr>
<td>Vatalanib</td>
<td>NCT00227773</td>
<td>Phase-II</td>
<td>Treatment</td>
<td>TK Inhibitors</td>
</tr>
<tr>
<td>Axitinib</td>
<td>NCT01435122</td>
<td>Phase-II</td>
<td>Safety/ Efficacy Study, Open Label</td>
<td>TK Inhibitors</td>
</tr>
<tr>
<td>Regorafenib</td>
<td>NCT02259725</td>
<td>Phase-II</td>
<td>Efficacy Study, Open Label</td>
<td>TK Inhibitors</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>NCT00075439</td>
<td>Phase-II</td>
<td>Efficacy Study, Open Label</td>
<td>TK Inhibitors</td>
</tr>
<tr>
<td>Dovitinib</td>
<td>NCT02108782</td>
<td>Phase-II</td>
<td>Efficacy Study, Open Label</td>
<td>TK Inhibitor</td>
</tr>
<tr>
<td>Farnitinib</td>
<td>NCT01994213</td>
<td>Phase-II</td>
<td>Safety/ Efficacy Study, Open Label</td>
<td>TK Inhibitors</td>
</tr>
<tr>
<td>X-82</td>
<td>NCT01784861</td>
<td>Phase-I/II</td>
<td>Safety/ Efficacy Study, Open Label</td>
<td>TK Inhibitor</td>
</tr>
<tr>
<td>Dactolisib (BEZ235)</td>
<td>NCT01628913</td>
<td>Phase-II</td>
<td>Safety/ Efficacy Study, Open Label</td>
<td>PI3K/mTOR Inhibitor</td>
</tr>
<tr>
<td>BYL-719</td>
<td>NCT02077933</td>
<td>Phase-I</td>
<td>Safety/ Efficacy Study, Open Label</td>
<td>PI3K Inhibitor</td>
</tr>
</tbody>
</table>

Temsrilimus

An ester analog of rapamycin. Temsrolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.

Proteasome inhibitors

Non-FDA approved proteasome inhibitors: There is no proteasome inhibitor that is currently approved by FDA for GEP-NETs. However, the below mentioned proteasome inhibitors are under clinical trials in Phase-II [58-59].

Carfilzomib: An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S proteasome, an enzyme responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.

Bortezomib: It is 26S proteasome inhibitor with anticancer properties. By inhibiting it, bortezomib hampers several signaling pathways. This results in cell cycle arrest, differentiation and antiangiogenesis. It also acts as NF-kappaB inhibitor and hence reduces cell survival, angiogenesis and growth of tumor.

Monoclonal antibodies (MABs)

Non-FDA Approved MABs: There are no MABs that are currently approved by FDA for GEP-NETS [60-65]. However, many MABs are under clinical trials in phase I-III as mentioned below:

Bevacizumab: It is a recombinant monoclonal antibody that acts against the pro-angiogenic cytokine, VEGF. It acts by adhering to VEGF and prevents it binding to its receptor, hence affecting tumor growth and associated blood vessels.

Ganitumab: It is an IGF-1R inhibitor monoclonal antibody having anti-neoplastic activity. It adheres to IGF-1R and triggers a cascade of signals resulting in inhibition of PI3K/Akt pathway, thus, inhibiting cell proliferation and apoptosis.

Pertuzumab: It is an HER-2 tyrosine kinase receptor inhibitor monoclonal antibody. It inhibits dimerization of receptor and protein.
This results in inactivation of HER signaling pathways and favors apoptosis.

**Cixutumumab:** It is a complete human monoclonal body derived from IgG1 and possesses anti-neoplastic activity. It adheres to the IGF-1R and hence, inhibits the PI3K/AKT pathway activation resulting in tumor cell death.

**Heat shock protein inhibitors:**

**Non-FDA Approved Heat Shock Protein Inhibitors:** There are no heat shock protein inhibitors that are currently approved by FDA for GEP-NETs. However, many are under clinical trials in phase I-III as mentioned in the Table 2.

**Cytokine therapy**

**Non-FDA approved cytokine therapy:** There is no cytokine therapy that is currently approved by FDA for GEP-NETs. However, the cytokine therapy available for GEP-NETs that are under clinical trials in phase I-III are as in the Table 3:

**Growth factor inhibitors**

**Non-FDA approved growth factor inhibitors:** There is no growth factor inhibitor that is currently approved by FDA for GEP-NETs [71]. However, some therapies are under clinical trials in phase I-III for GEP-NETs as mentioned below:

**Romidepsin:** It is an antineoplastic antibiotic derived from the bacterium Chromobacterium violaceum. It is an HDAC inhibitor that alters gene expression, resulting in the halt of cell cycle, apoptosis and inhibition of proliferation of cells.

**Cytokine therapy**

**Non-FDA approved cytokine therapy:** There is no cytokine therapy that is currently approved by FDA for GEP-NETs. However, the cytokine therapy available for GEP-NETs that are under clinical trials in phase I-III are as in the Table 3:

**Growth factor inhibitors**

**Non-FDA approved growth factor inhibitors:** There is no growth factor inhibitor that is currently approved by FDA for GEP-NETs [72-73]. Clinical trials undergoing in phase I-III are as mentioned below:

**Ziv-Aflibercept:** It is a recombinant protein that blocks VEGF to adhere to its respective receptor resulting in inhibition of angiogenesis, metastasis and tumor growth.

**Somatostatin analogues**

**FDA approved somatostatin analogues**

**Lanreotide:** It was approved by the FDA on December 16, 2014, the U. S. Food and Drug Administration approved lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. Lanreotide was previously approved for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option [74].

It binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compared to octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-1). This agent is usually given as a prolonged-release microparticulate or autogel formulation for the treatment of acromegaly and to relieve the symptoms of NETs.

**Non-FDA approved somatostatin analogues [75]**

Some of the other clinical trials going on for GEP-NETs are mentioned below:

**Sandostatin LAR:** It is a somatostatin analogue that adheres to these receptors. This receptor is proposed to be expressed in NETs and is responsible for apoptosis, mediated through a somatostatin receptor. Along with this, it also affects the process of angiogenesis and insulin like growth factor 1 (IGF-1).

**Conclusion**

GEP-NETs belong to the class of NETs. It is a rare cancer and MEN 1 is the major predisposing factor associated with them. Alterations and loss of various chromosomes result in the progression of GEP-NETs. Researchers are still challenged in exploring innate and adaptive immune systems. Immunotherapy has shown a promising development in the past few years. Although, there are very few FDA approved immunotherapeutic agents available for GEP-NETs, a number of clinical trials are ongoing for various classes like MABs, adoptive therapy, vaccines and TK inhibitors. The complete perspective of immunotherapy treatment has not been realized and/or utilized. Proper preclinical and clinical designs are the important pillars in understanding the future of immunotherapy in treating cancer patients.

**References**


**Table 2. Non-FDA approved heat shock protein inhibitors [67]**

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Heat shock protein inhibitors</th>
<th>Clinical trial identifier number</th>
<th>Phase</th>
<th>Study design</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>NETs</td>
<td>SNX-5422</td>
<td>NCT02063958</td>
<td>Phase-I</td>
<td>Safety Study, Open Label</td>
<td>Hsp90</td>
</tr>
</tbody>
</table>

**Table 3. Non-FDA approved cytokine therapy [68-70]**

<table>
<thead>
<tr>
<th>Cytokine Therapy</th>
<th>Clinical trial identifier number</th>
<th>Phase</th>
<th>Study design</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal NETs</td>
<td>Recombinant Interleukin-12</td>
<td>NCT00004074</td>
<td>Phase-I</td>
<td>Safety Study, Open Label</td>
</tr>
<tr>
<td>Gastrointestinal NETs</td>
<td>Recombinant Interferon- alpha</td>
<td>NCT00002470</td>
<td>Phase-II</td>
<td>Treatment</td>
</tr>
<tr>
<td>Gastrointestinal NETs</td>
<td>Interferon alpha-2b</td>
<td>NCT00055809</td>
<td>Phase-II</td>
<td>Efficacy Study, Open Label</td>
</tr>
</tbody>
</table>


36. FDA label SUTENT® (sunitinib malate). Distributed by Pfizer Labs Division of Pfizer Inc New York, NY 10017.


56. FDA label AFINITOR® (everolimus). manufactured by: novartis pharma stein agstein, switzerland. distributed by: novartis pharmaceuticals corporation east hanover, New Jersey 07936.


74. US food and drug administration (FDA) http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427065.htm


Copyright: ©2019 Allen T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.